Impact of Therapy Using Colesevelam Treatment Reducing Bile Acids in Patients With Fontan Circulation.
Status:
Not yet recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This is the first pilot study proposing a novel therapeutic option treating patients with
Fontan circulation (FC), a high-risk condition that has no definite treatment options
available, other than heart or heart-liver transplantation. The investigator's identification
of elevated BA and their association with adverse clinical - investigational features in
Fontan patients are novel.